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Abstract
Background: Lung disease in patients with cystic fibrosis is thought to develop as a result of
airway inflammation, infection, and obstruction. Pulmonary therapies for cystic fibrosis that reduce
airway inflammation include corticosteroids, rhDNase, antibiotics, and high-dose ibuprofen.
Despite evidence that high-dose ibuprofen slows the progression of lung disease in patients with
cystic fibrosis, many clinicians have chosen not to use this therapy because of concerns regarding
potential side effects, especially gastrointestinal bleeding. However, studies have shown a low
incidence of gastrointestinal ulceration and bleeding in patients with cystic fibrosis who have been
treated with high-dose ibuprofen.
Case presentation: The described case illustrates a life-threatening upper gastrointestinal bleed
that may have resulted from high-dose ibuprofen therapy in a patient with CF who had undergone
a pneumonectomy. Mediastinal shift post-pneumonectomy distorted the patient's esophageal
anatomy and may have caused decreased esophageal motility, which led to prolonged contact of
the ibuprofen with the esophagus. The concentrated effect of the ibuprofen, as well as its systemic
effects, probably contributed to the occurrence of the bleed in this patient.
Conclusions: This report demonstrates that gastrointestinal tract anatomical abnormalities or
dysmotility may be contraindications for therapy with high-dose ibuprofen in patients with cystic
fibrosis.
Background
Airway inflammation is thought to cause much of the
lung damage in patients with cystic fibrosis (CF) [1,2].
Such inflammation has been found in infants with CF,
even in the absence of bacterial infections or symptomatic
lung disease [3].
Recent therapies for CF lung disease have been shown to
preserve lung function by decreasing airway exposure to
inflammation. For example, airway clearance, antibiotics
(inhaled tobramycin and oral azithromycin), rhDNase,
and oral corticosteroids have been used to help decrease
airway inflammation [4-6]. High-dose ibuprofen therapy
also has been shown to be effective in decreasing inflam-
mation, probably by decreasing polymorphonuclear cell
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influx into the lungs [7]. We present a patient with CF
who developed a rare complication of high-dose ibupro-
fen therapy related to his pneumonectomy.
Case presentation
The patient was a teenager with CF who suffered for sev-
eral years from right lower lobe consolidation, as a result
of recurrent Pseudomonas aeruginosa pneumonia. The con-
solidation was unresponsive to intensive therapy includ-
ing intravenous (IV) antibiotics, chest physiotherapy,
systemic steroids, and rhDNase. The patient developed
recurrent severe pulmonary exacerbations necessitating IV
antibiotic therapy 4 times per year between the ages of 14
and 15 years. A computerized tomography scan of the
chest when the patient was 15-years-old revealed com-
plete collapse of his right lung. A ventilation/perfusion
scan revealed only 8% of his ventilation and perfusion in
his right chest, while the remaining 92% was in his left
chest. In addition, the left lung had begun to herniate into
his right chest. It was felt that the right lung was a recur-
rent source of infection, which was causing serious mor-
bidity. Therefore, the patient underwent a total right
pneumonectomy that he tolerated well.
Approximately one year later, in preparation for initiating
high-dose ibuprofen therapy, the patient's stool was
checked for occult blood. He was found to have occa-
sional guaiac positive stools. An upper gastrointestinal
endoscopy revealed chronic esophagitis, esophageal
ulcerations, and Barrett's esophagus thought to be attrib-
utable to gastroesophageal reflux. A 24-hour pH probe
revealed significant gastroesophageal reflux despite anti-
reflux therapy. Therefore, a fundoplication was performed
in order to prevent further esophageal damage. Subse-
quently, it was believed that his esophageal ulcerations
resolved as multiple stools were documented to be guaiac
negative.
High-dose ibuprofen therapy was initiated when the
patient was 17-years-old, based on published recom-
mended dosage and pharmacokinetic protocols [8]. The
patient's dose was determined by a pharmacokinetic anal-
ysis [8] that documented a peak ibuprofen plasma con-
centration of 69 mcg/ml, following a test dose of 1,000
mg (22 mg/kg). A week after initiation of ibuprofen at a
dose of 1,000 mg b.i.d. the patient developed severe
abdominal pain, hematemesis and bright red blood per
rectum. He became hemodynamically compromised and
an emergency endoscopy revealed bleeding esophageal
ulcerations in the distal 12 cm of his esophagus. After sta-
bilization and observation without further bleeding, a
barium swallow demonstrated that his esophagus was
deviated towards the right side and the lower segment of
the esophagus was relatively horizontal proximal to the
gastro-esophageal junction (Figure 1). In addition, a pan-
creatic enzyme capsule emptied of the enzymes and filled
with barium was retained within that esophageal segment
for several minutes (Figure 1).
Following this episode the patient's ibuprofen was discon-
tinued, and his oral medications (e.g., antibiotics and
vitamins) were switched to liquid form, whenever possi-
ble. His pancreatic enzymes were administered after
removing the enzyme microspheres from their capsule
and mixing them in applesauce.
Reported complications of pneumonectomy include
mediastinal shift with herniation of the remaining lung,
cardiac herniation, cardiac arrhythmias, bronchopleural
fistula, esophageal motility disorders, and development
of scoliosis [9-11]. It is thought that pediatric patients
have more mediastinal shift following pneumonectomy
than adults because of increased elasticity and compliance
of the lung and mediastinum that allow for more severe
anatomical derangements [9]. A study of 17 post-pneu-
monectomy pediatric patients revealed that all of the
patients had marked herniation of the remaining lung
with a mediastinal shift to the opposite side as evident on
chest radiographs or computerized tomography scans
[11]. One patient with a right pneumonectomy displayed
excessive shift of the esophagus as well, but did not have
any associated dysphagia or reflux [11]. In another study,
esophageal motility was measured in 13 patients before
and after pneumonectomy [9]. Patients post-pneumonec-
tomy were shown to have esophageal dysmotility even
without reporting dysphagia [9]. The dysmotility was
thought to be attributable to the mediastinal shift [9].
Thus, for the patient in the present report, it is likely that
the deleterious effects of gastroesophageal reflux may
have been increased because of esophageal dysmotility
after pneumonectomy.
In our patient, esophageal dysmotility along with the dis-
tortion of esophageal anatomy probably combined to
slow the esophageal transit time of the ingested ibupro-
fen, which may have led to development of ulcerations as
a result of prolonged concentrated contact within the
esophagus. Also, the ibuprofen could have contributed to
the development of ulcerations by inhibiting cyclooxyge-
nase systemically, which decreased prostaglandin E pro-
duction [12]. In turn, less prostaglandin E was available to
promote bicarbonate and mucus secretion, which are pro-
tective of the gastrointestinal mucosa [12].
Delayed esophageal transit may have occurred with the
patient's other oral medications prior initiation of ibupro-
fen. For example, his pancreatic enzymes likely were
retained in the same esophageal segment, which placed
him at risk of developing esophageal damage akin to the
development of fibrosing colonopathy and stricturesBMC Pediatrics 2004, 4:19 http://www.biomedcentral.com/1471-2431/4/19
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Barium swallow in a patient with cystic fibrosis following right pneumonectomy Figure 1
Barium swallow in a patient with cystic fibrosis following right pneumonectomy. A – The study demonstrates deviation of 
esophagus to the right side, and a relatively horizontal lower esophageal segment proximal to the gastro-esophageal junction. B 
– A pancreatic enzyme capsule emptied of the enzymes and filled with barium (indicated by the arrow) is retained within the 
lower esophagus for several minutes.BMC Pediatrics 2004, 4:19 http://www.biomedcentral.com/1471-2431/4/19
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described in patients with CF who received high-dose
pancreatic enzymes [13]. The enzymes may have
remained inactive because the environment was not alka-
line enough for their activation [14], which may be the
reason that the patient did not demonstrate esophageal
strictures.
According to the 2002 CF Foundation registry, only 3.8%
of patients in North America with CF were treated with
high-dose ibuprofen [15]. In 1999, a survey of 67 CF
center physicians revealed that safety issues were a major
reason that they did not prescribe this therapy [16]. Gas-
trointestinal bleeding, a known adverse effect of non-ster-
oidal anti-inflammatory agents, was the safety issue of
most concern to these physicians [16]. Other known side-
effects of high-dose ibuprofen include renal failure (often
transient), and epistaxis [3,17].
The initial randomized, double-blind, placebo control
study of high-dose ibuprofen in CF did not demonstrate
serious side effects during 4 years of therapy with ibupro-
fen sufficient to achieve peak plasma concentrations of
50–100 mcg/L [8]. Seven of 85 study patients developed
abdominal pain, while only 2 of these 7 were on ibupro-
fen. One patient in the placebo group developed esophag-
itis. Of note, abdominal pain, which is very common in
patients with CF, actually improved in many patients. In
another randomized, double-blind, placebo controlled
study, involving 19 children with cystic fibrosis; 13 chil-
dren received sufficient ibuprofen for 26 months to max-
imum concentrations 48 +/- 17 mcg/ml, but no adverse
effects could be attributed to the ibuprofen [18].
The incidence of gastrointestinal disease in patients
reported to the CF Foundation registry from 1996–2000,
was compared between patients who were and were not
taking ibuprofen [19]. Peptic ulcer disease was reported in
0.32% of 1,186 CF patients taking high-dose ibuprofen,
as compared to an incidence of 0.22% in 18,587 patients
not taking ibuprofen. Gastrointestinal bleeding was
reported in 0.49% of patients taking ibuprofen, as com-
pared to 0.23% of the others (p = .0004). In the first year
after initiation of high-dose ibuprofen therapy for 91
patients at the Texas Children's Hospital CF Center, one
patient developed upper gastrointestinal bleeding, and
one developed gastritis [20]. In a published case report, a
12-year-old patient with CF on high-dose ibuprofen
developed emesis and feeding intolerance [21]. She was
found to have pyloric channel stricture as a result of heal-
ing antral and pyloric ulcers, which may have been caused
by ibuprofen.
Conclusions
The risk of developing gastrointestinal side-effects from
high-dose ibuprofen therapy is low for patients with CF.
However, ibuprofen may be contraindicated for those
who are at increased risk because of gastroesophageal
reflux, history of gastrointestinal ulcerations, or abnormal
gastrointestinal motility or anatomy.
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